We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bbr7.5
Berberine Research
Likely helps
209 peer-reviewed studies
What the evidence says
Likely helps
Berberine appears to help in 4 of 4 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1985–2027 with a typical study size of 1,386 participants.
Based on 209 studies · 40 meta-analyses · 79 RCTs · 44,507 total participants
Confidence
High confidence
What the studies found
4helped· 205 more without graded effect data
By outcome
Glucose & metabolicSignificant HbA1c reduction in type 2 diabetes trials. The one head-to-head with metformin cited here was a 36-person pilot, not evidence it can replace metformin · 2-4 weeks · Activates AMPK; improves insulin sensitivity, lipids, mitochondrial function · 4-12 weeks
InflammationMeta-analyses of RCTs report modest reductions in CRP, IL-6 and TNF-a from heterogeneous, low-quality trials, and better clinical response in ulcerative colitis as an add-on to 5-ASA · 4-12 weeks
Too few graded studies11 studies
Cognitive function
Mostly mechanism / observational7 studies
By the numbers
Pulled from 49 studies with measurable effects
Likely real effects
100%
across studies
People studied
45k
typical study: 1386 people
Strongest designs
119
40 pooled, 79 randomised
Showed benefit
100%
4/4 studies
How long studies ran
1–4 weeks
2
1–3 months
4
3+ months
1
Populations Studied
Type 2 diabetes patients4
Cardiovascular disease patients2
NAFLD patients2
Patients with Type 2 Diabetes Mellitus1
Active research area
146 studies in the last 5 years · Latest meta-analysis: 2026
198520062027
1HbA1c reductionMeta-AnalysisCited 4×n=1,337 · large study2025
In plain English: However, further validation of these findings is necessary through extensive clinical studies with larger sample sizes.
Miao R et al. · Phytotherapy research : PTR (2025)
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
For body mass index (BMI), curcumin was more effective than resveratrol (MD -1.27, 95%Cl -2.43 to -0.03) (P < 0.05).
Curcumin, resveratrol, silymarin, and berberine can effectively improve cardio-metabolic risk factors in T2DM, and different herbal phytochemicals have different clinical advantages.
3Inflammatory biomarkers reductionMeta-AnalysisCited 13×n=1,600 · large study2023
In plain English: However, more investigation and high-quality evidence must be conducted to obtain more comprehensive and generalizable results.
Vahedi-Mazdabadi Y et al. · Phytotherapy research : PTR (2023)
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
There are limitations to our findings, including low-quality studies and significant heterogeneity.
These interventions might be considered adjunct therapy to managing inflammation status.
4Meta-AnalysisCited 26×n=4,606 · very large study2023
In plain English: This study suggests that berberine may be a promising alternative for CVDs with no serious adverse reactions.
Yang L et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology (2023)
Berberine alone significantly reduced National Institute of Health Stroke Scale (NIHSS) score, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intima-media thickness (IMT) levels than routine therapy.
Berberine plus statins significantly reduced TC, TG, LDL-C, NIHSS score, hs-CRP, TNF-α, IMT, Crouse score, and number of unstable plaques levels than routine or statins.
This study suggests that berberine may be a promising alternative for CVDs with no serious adverse reactions.
5Glycemic control improvementMeta-AnalysisCited 15×2024
In plain English: The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.
In plain English: Higher quality studies are needed to provide more high quality evidence.
Zhang LS et al. · The American journal of Chinese medicine (2019)
The results of meta-analysis showed that compared with the placebo group, berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level ( P<0.05 ).
Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ).
Compared with the simvastatin group, berberine plus simvastatin was more effective in reducing the level of triglyceride ( MD=-0.33 , 95% CI: - 0.46, - 0.20, P<0.00001 ) and total cholesterol ( MD=-0.36 , 95% CI: - 0.60, - 0.12, P=0.003 ).
10Meta-AnalysisCited 93×n=2,313 · very large study2019
In plain English: The dosage and treatment duration of Berberine and patients' age may modify the effect.
Liang Y et al. · Endocrine journal (2019)
We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels.
The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups.
Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years.
11Meta-AnalysisCited 330×n=2,569 · very large study2015
In plain English: This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Lan J et al. · Journal of ethnopharmacology (2015)
This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Considering the relatively low cost compared with other first-line medicine and treatment, berberine might be a good alternative for low socioeconomic status patients to treat type 2 DM, hyperlipidemia, hypertension over long time period.
Due to overall limited quality of the included studies, the therapeutic benefit of berberine can be substantiated to a limited degree.